Causes of death and re-hospitalization in cardiogenic shock

Acute Cardiac Care

Volumn 9, Issue 1, 2007, Pages 25-33

  Jeger, Raban V ^a   Assmann, Susan F ^b   Yehudai, Loran ^a   Ramanathan, Krishnan ^a   Farkouh, Michael E ^a   Hochman, Judith S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

Arrhythmia; Cardiogenic shock; Cause of death; Hospitalization; Sepsis syndrome

Indexed keywords

FIBRINOLYTIC AGENT; HYPERTENSIVE FACTOR; INOTROPIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SEPSIS; SUDDEN DEATH; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE;

AGED; CAUSE OF DEATH; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PATIENT READMISSION; RISK ASSESSMENT; RISK FACTORS; SHOCK, CARDIOGENIC; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 34247263756     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940601178039     Document Type: Article

References (38)

1. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340:1162-8.
2. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med. 1994;330:1724-30.
3. Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR, Jr. Cardiogenic shock complicating acute coronary syndromes. Lancet. 2000;356:749-56.
4. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190-2.
5. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? N Engl J Med. 1999;341:625-34.
6. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358-61.
7. Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. 2003;24:1287-95.
8. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998-3002.
9. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190:244-54.
10. Liuzzo G, Buffon A, Biasucci LM, Gallimore JR, Caligiuri G, Vitelli A, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98:2370-6.
11. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748-55.
12. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12.
13. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462-6.
14. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-24.
15. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med. 1999;131:47-59.
16. Hochman JS, Sleeper LA, Godfrey E, McKinlay SM, Sanborn T, Col J, et al. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK: an international randomized trial of emergency PTCA/CABG-trial design. Am Heart J. 1999;137:313-21.
17. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 1999;31:1250-6.
18. Kohsaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med. 2005;165:1643-50.
19. Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest. 2003;124:1885-91.
20. Valencia R, Theroux P, Granger CB, Mahaffey KW, Gudaye T, Malloy K, et al. Congestive heart failure and cardiogenic shock complicating acute myocardial infarction have high mortality and are associated with intense inflammatory response: results from the CARDINAL trials (abstract). J Am Coll Cardiol. 2004;43:A291.
21. Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, et al. Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med. 2002;30:1987-94.
22. Dzavik V, Cotter G, Farkouh ME, Ramanathan K, Reynolds HR, Baran D, et al. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with acute myocardial infarction complicated by cardiogenic shock: a phase 2 dose ranging study (abstract). Circulation 2004; 110.
23. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-90.
24. Menon V. Cardiogenic shock: have we really found the magic potion? Eur Heart J. 2003;24:1279-81.
25. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J. 2005;26:1964-70.
26. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581-8.
27. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-8.
28. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-4.
29. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
30. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-31.
31. Tortolani AJ, Risucci DA, Rosati RJ, Dixon R. In-hospital cardiopulmonary resuscitation: patient, arrest and resuscitation factors associated with survival. Resuscitation. 1990;20:115-28.
32. Tunstall-Pedoe H, Bailey L, Chamberlain DA, Marsden AK, Ward ME, Zideman DA. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. BMJ. 1992;304:1347-51.
33. Epstein AE, Powell J, Yao Q, Ocampo C, Lancaster S, Rosenberg Y, et al. In-hospital versus out-of-hospital presentation of life-threatening ventricular arrhythmias predicts survival: results from the AVID Registry. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol. 1999;34:1111-6.
34. Gwinnutt CL, Columb M, Harris R. Outcome after cardiac arrest in adults in UK hospitals: effect of the 1997 guidelines. Resuscitation. 2000;47:125-35.
35. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26:1276-83.
36. Keenan SP, Dodek P, Chan K, Hogg RS, Craib KJ, Anis AH, et al. Intensive care unit admission has minimal impact on long-term mortality. Crit Care Med. 2002;30:501-7.
37. Keenan SP, Dodek P, Chan K, Simon M, Hogg RS, Anis AH, et al. Intensive care unit survivors have fewer hospital readmissions and readmission days than other hospitalized patients in British Columbia. Crit Care Med. 2004;32:391-8.
38. Desideri A, Fioretti PM, Cortigiani L, Gregori D, Coletta C, Vigna C, et al. Cost of strategies after myocardial infarction (COSTAMI): a multicentre, international, randomized trial for cost-effective discharge after uncomplicated myocardial infarction. Eur Heart J. 2003;24:1630-9.